- Conditions
- Anaplastic Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma
- Interventions
- tanespimycin
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 3001–3024
of 21,430
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- oblimersen sodium, docetaxel
- Biological · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2002
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Myeloma
- Interventions
- Arsenic Trioxide, Ascorbic Acid and Bortezomib
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Alopecia Areata
- Interventions
- Crisaborole Topical Ointment, Placebo Topical Ointment
- Drug
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 2 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Alport Syndrome
- Interventions
- Placebo Oral Capsule, Bardoxolone Methyl
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 32 more
- Conditions
- Recurrent Bladder Carcinoma, Stage I Bladder Cancer AJCC v6 and v7, Stage II Bladder Cancer AJCC v6 and v7, Stage III Bladder Cancer AJCC v6 and v7
- Interventions
- Genistein, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration, Therapeutic Conventional Surgery
- Drug · Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Laguna Hills, California • Iowa City, Iowa + 6 more
- Conditions
- Colorectal Cancer
- Interventions
- capecitabine, Oxaliplatin, Irinotecan
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- HIV Infections
- Interventions
- Oral HIV screening, Fingerstick HIV screening
- Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,651 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Mucopolysaccharidosis II
- Interventions
- Genetic HMI-203
- Biological
- Lead sponsor
- Homology Medicines, Inc
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 5
- States / cities
- Oakland, California • New Haven, Connecticut • Hackensack, New Jersey + 2 more
- Conditions
- Irritable Bowel Syndrome, Diarrhea
- Interventions
- LY3537031, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 531 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 15
- States / cities
- Mesa, Arizona • Anaheim, California • Lancaster, California + 12 more
- Conditions
- Heart Failure
- Interventions
- vicadrostat, empagliflozin, placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6,712 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 94
- States / cities
- Mobile, Alabama • Chula Vista, California • Orange, California + 81 more
- Conditions
- Dystrophic Epidermolysis Bullosa
- Interventions
- Topical beremagene geperpavec, Placebo gel
- Biological
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Prostate Cancer Metastatic, Prostate Cancer, CRPC
- Interventions
- Enhertu
- Drug
- Lead sponsor
- Washington D.C. Veterans Affairs Medical Center
- Federal
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Breast Cancer
- Interventions
- cyclophosphamide, docetaxel, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, radiation therapy
- Drug · Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2016
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 30 more
- Conditions
- Pancreatic Cancer, Neoplasm Metastasis, Adenocarcinoma
- Interventions
- talabostat mesylate tablets, gemcitabine
- Drug
- Lead sponsor
- Point Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 28
- States / cities
- Florence, Alabama • Muscle Shoals, Alabama • Hartford, Connecticut + 20 more
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Nab-Paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Fluorouracil, Atezolizumab, Cobimetinib, PEGPH20, BL-8040, Selicrelumab, Bevacizumab, RO6874281, AB928, Tiragolumab, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 12
- States / cities
- Duarte, California • San Francisco, California • New Haven, Connecticut + 8 more
- Conditions
- Transplant Rejection
- Interventions
- BIVV020 (SAR445088), Intravenous immunoglobulin (IVIg), Rituximab or biosimilar, Antithymocyte globulin (ATG), Tacrolimus, Mycophenolate, Corticosteroids
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more
- Conditions
- Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage IV Adult Hodgkin Lymphoma
- Interventions
- brentuximab vedotin, doxorubicin hydrochloride, vinblastine, dacarbazine, quality-of-life assessment, DNA analysis, RNA analysis, fludeoxyglucose F 18, positron emission tomography, laboratory biomarker analysis, immunohistochemistry staining method, polymorphism analysis
- Drug · Procedure · Genetic + 2 more
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 7
- States / cities
- Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more
- Conditions
- Adult Brain Tumor, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Interventions
- conventional surgery, tandutinib, pharmacological study, Tissue samples
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more
- Conditions
- Metastatic Uveal Melanoma
- Interventions
- ZIV-Aflibercept, Cemiplimab
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Tampa, Florida • Chicago, Illinois + 1 more
- Conditions
- Neuroblastoma
- Interventions
- Tipifarnib, Naxitamab
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2035
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • Hartford, Connecticut • Miami, Florida + 9 more
- Conditions
- Lung Cancer
- Interventions
- Motexafin Gadolinium
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 7
- States / cities
- La Verne, California • Rochester, New York • Canton, Ohio + 4 more
- Conditions
- Sarcoma
- Interventions
- filgrastim, doxorubicin hydrochloride, ifosfamide, mesna, vincristine sulfate, conventional surgery, brachytherapy, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2006
- U.S. locations
- 7
- States / cities
- Wichita, Kansas • New Orleans, Louisiana • Memphis, Tennessee + 4 more
- Conditions
- Acne Vulgaris
- Interventions
- IDP-120 Gel, IDP 120 Component A Gel, IDP 120 Component B Gel, IDP 120 Vehicle Gel
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 9 Years and older
- Enrollment
- 364 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 20
- States / cities
- Encino, California • Lake Mary, Florida • Miami, Florida + 15 more